<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-139685</identifier>
<setSpec>1138-3593</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">A review of multiple sclerosis (2). Diagnosis and treatment</dc:title>
<dc:description xml:lang="en">Multiple sclerosis is a major demyelinating disease of the central nervous system. It has a significant economic and social impact. Its etiology is unclear, although there are several hypotheses, such as infections or genetics. In its pathophysiology, it seems that immune activation attacks the myelin sheath, causing a progressive and irreversible axonal degeneration. The disease produces a variety of symptoms, and diagnosis requires fulfilling a number of criteria and the exclusion of other possible causes. The role of neuroimaging is very important, especially Magnetic Resonance Imaging. Despite the availability of disease-modifying drugs, none of them are able to halt its progress, and the most useful drugs are those designed to alleviate the symptoms of outbreaks. Overall, multiple sclerosis requires a significant effort in research to clarify not only why and how it occurs, as well as the development of new measures to improve quality of life of affected patients (AU)</dc:description>
<dc:creator>Luna-Calcaño, IM</dc:creator>
<dc:creator>Martinez-Altarriba, MC</dc:creator>
<dc:creator>Arrieta-Antón, E</dc:creator>
<dc:creator>Ramos-Campoy, O</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La esclerosis múltiple (EM) es una de las principales enfermedades desmielinizantes del sistema nervioso central. Importante impacto económico social. Etiología no clara, se barajan hipótesis como la infecciosa o factores genéticos. La fisiopatología parece una activación inmunitaria que atacaría a las vainas de mielina, causando degeneración axonal progresiva e irreversible. Los síntomas son muy variados, su diagnóstico exige el cumplimiento de una serie de criterios y exclusión de otras causas posibles. Además es importante el papel de la neuroimagen, principalmente la RM. A pesar de disponer de fármacos modificadores de la enfermedad, todavía no hay ninguno que frene su evolución, fármacos útiles son los orientados a paliar la sintomatología de brotes. En conjunto, la EM requiere importante esfuerzo de investigación que aclare no solo por qué y cómo se produce, sino también el desarrollo de nuevas medidas que mejoren la vida de los pacientes afectados (AU)</dc:description>
<dc:source>SEMERGEN, Soc. Esp. Med. Rural Gen. (Ed. Impr.);41(6): 324-328, sept. 2015. tab, ilus</dc:source>
<dc:identifier>ibc-139685</dc:identifier>
<dc:title xml:lang="es">Revisión de la esclerosis múltiple (2). Diagnóstico y tratamiento</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d9296^s22067</dc:subject>
<dc:subject>^d9296^s22016</dc:subject>
<dc:subject>^d11812</dc:subject>
<dc:subject>^d9296^s22027</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d3965</dc:subject>
<dc:subject>^d2594^s22031</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d5168^s22031</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d5168^s22021</dc:subject>
<dc:subject>^d22935^s22045</dc:subject>
<dc:subject>^d28589^s22054</dc:subject>
<dc:subject>^d23405^s22045</dc:subject>
<dc:subject>^d9296^s29166</dc:subject>
<dc:subject>^d11756^s22045</dc:subject>
<dc:subject>^d9296^s22032</dc:subject>
<dc:type>article</dc:type>
<dc:date>201509</dc:date>
</metadata>
</record>
</ibecs-document>
